| Title: |
Human Metapneumovirus: an emerging respiratory pathogen and the urgent need for improved Diagnostics, surveillance, and vaccine development. |
| Authors: |
Akingbola, Adewunmi1 (AUTHOR), Adegbesan, Abiodun2 (AUTHOR), TundeAlao, Samuel3 (AUTHOR), Adewole, Olajumoke4 (AUTHOR), Ayikoru, Comfort1 (AUTHOR), Benson, Akpevwe Emmanuella5 (AUTHOR), Shekoni, Mayowa4 (AUTHOR), Chuku, Joel6 (AUTHOR) chuku2016.6391200@student.karazin.ua |
| Source: |
Infectious Diseases. Mar2025, Vol. 57 Issue 3, p304-310. 7p. |
| Subject Terms: |
*HUMAN metapneumovirus infection, *VACCINE development, *DIAGNOSIS methods, *AT-risk people, *RESPIRATORY diseases, *HEALTH facilities, *RESPIRATORY infections, *SCIENTIFIC observation |
| Abstract: |
Human Metapneumovirus (HMPV) is a re-emerging respiratory pathogen causing significant morbidity and mortality, particularly among young children, the elderly, and immunocompromised individuals. First identified in 2001, HMPV has since been recognised as a leading cause of acute respiratory tract infections (ARTIs) worldwide. Its transmission occurs through droplets, direct contact, and surface contamination, with crowded spaces and healthcare facilities serving as key environmental amplifiers. HMPV's clinical manifestations, ranging from mild cold-like symptoms to severe pneumonia, often overlap with those of other respiratory pathogens like RSV and COVID-19, complicating timely diagnosis and management. Despite advancements in molecular diagnostics, the limited accessibility of these tools in low-resource settings presents a challenge. Preventive measures, such as hygiene practices and physical distancing, remain critical, as no approved vaccines or targeted antiviral therapies are currently available. However, promising innovations, including AI-guided vaccine design and portable diagnostic tools, highlight the potential for future breakthroughs. This article highlights the urgent need for enhanced surveillance, scalable diagnostics, and intensified research into vaccines and therapeutic strategies. By addressing these gaps, HMPV's global burden can be significantly mitigated, improving outcomes for high-risk populations, and strengthening preparedness against respiratory virus outbreaks. [ABSTRACT FROM AUTHOR] |
|
Copyright of Infectious Diseases is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
